Ftse Mib
36.685,83
1,29%
DAX
21.505,70
0,47%
S&P 500
6.024,73
0,50%
NASDAQ
19.621,37
1,18%
Bitcoin
99.120,00
-2,27%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Summit Therapeutics Inc (SMMT) Summit Therapeutics Inc (SMMT) Notizie

Summit Therapeutics Inc

SMMT
20,433
0,453 (2,27%)
Ultimo aggiornamento: 18:08:33
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/1/202522:23EDGAR2Form 8-K - Current report
16/1/202522:15BWSummit Therapeutics Reports Inducement Grants Under Nasdaq..
14/1/202522:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/1/202514:37EDGAR2Form 8-K - Current report
07/1/202513:00BWSummit Therapeutics to Present at the 43rd Annual J.P...
07/1/202501:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/1/202501:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202422:15BWSummit Therapeutics Reports Inducement Grants Under Nasdaq..
26/11/202422:15BWSummit Therapeutics to Present at Upcoming Investor..
21/11/202422:15BWSummit Therapeutics Reports Inducement Grants Under Nasdaq..
30/10/202412:33EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
30/10/202412:06EDGAR2Form 8-K - Current report
30/10/202412:00BWSummit Therapeutics Reports Operational Progress and..
23/10/202422:15BWSummit Therapeutics to Host Third Quarter 2024 Financial..
04/10/202422:15BWSummit Therapeutics Reports Inducement Grants Under Nasdaq..
03/10/202422:15BWSummit Therapeutics Announces Completion of Enrollment in..
19/9/202423:28EDGAR2Form S-3ASR - Automatic shelf registration statement of..
16/9/202412:30BWPromising Anti-Tumor Activity and Safety of Ivonescimab in..
13/9/202423:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202412:49EDGAR2Form 8-K - Current report
12/9/202412:30BWSummit Therapeutics Raises $235 Million
09/9/202413:23EDGAR2Form 8-K - Current report
08/9/202417:45BWIvonescimab Monotherapy Reduced the Risk of Disease..
06/9/202422:15BWSummit Therapeutics Reports Inducement Grants Under Nasdaq..
12/8/202413:00BWHARMONi-2, Featuring Ivonescimab Monotherapy vs...
12/8/202401:30PRNUSTwo Ivonescimab (PD-1/VEGF) Results including Phase 3..
09/8/202422:15BWSummit Therapeutics Reports Inducement Grants Under Nasdaq..
06/8/202415:03EDGAR2Form S-3ASR - Automatic shelf registration statement of..
06/8/202413:37EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/8/202413:14EDGAR2Form 8-K - Current report
06/8/202413:00BWSummit Therapeutics Reports Financial Results and..
29/7/202422:15BWSummit Therapeutics to Host Second Quarter 2024 Financial..
25/7/202414:00BWSummit Therapeutics and MD Anderson Announce Strategic..
03/7/202422:15BWSummit Therapeutics Reports Inducement Grants Under Nasdaq..
27/6/202422:15BWSummit Therapeutics Appoints Jeff Huber, Transformational..
18/6/202423:14EDGAR2Form D - Notice of Exempt Offering of Securities
17/6/202423:25EDGAR2Form 8-K - Current report
13/6/202420:03EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
03/6/202412:18EDGAR2Form 8-K - Current report
03/6/202412:05EDGAR2Form 8-K - Current report
03/6/202411:30BWSummit Raises $200 Million; Also Expands License Territories..
01/6/202414:00BWIvonescimab Manuscript for HARMONi-A Clinical Trial Results..
01/6/202401:00BW Ivonescimab in Combination with Chemotherapy Approved in..
31/5/202400:00BWSummit Therapeutics Reports Inducement Grants Under Nasdaq..
30/5/202422:48EDGAR2Form 8-K - Current report
30/5/202420:29BWIvonescimab Monotherapy Decisively Beats Pembrolizumab..
24/5/202414:35EDGAR2Form 8-K - Current report
13/5/202414:03EDGAR2Form 8-K - Current report
13/5/202413:48EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/5/202413:00BWSummit Therapeutics Reports Financial Results and..
Apertura: 20,00 Min: 19,90 Max: 20,89
Chiusura: 19,98

La tua Cronologia

NASDAQ
SMMT
Summit Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci